Home›Trial›NCT07020832
🔬NCT07020832Phase 3RECRUITING

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Study Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Conditions
Delayed Graft FunctionEnd Stage Renal DiseaseDeceased Donor Kidney Transplant
Interventions / Drugs
PegcetacoplanPlacebo
View on ClinicalTrials.gov ↗
Sponsor
APLS
Apellis Pharmaceuticals
Complement Inhibitors
D36/100
Study Details
Enrollment320 participants
Primary Completion—
Lead SponsorApellis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:54:08.046018+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.